When Could Uptravi Go Generic?
The patent protecting Uptravi (selexipag) is expected to expire in 2026 [1]. This expiration date is a key factor in determining when generic versions of the drug might become available.
What Happens When Uptravi's Patent Expires?
Following patent expiration, the U.S. Food and Drug Administration (FDA) may approve generic versions of Uptravi, provided they meet bioequivalence standards [2]. Generic drugs typically cost less than their brand-name counterparts, increasing accessibility.
What is Uptravi Used For?
Uptravi is a medication used to treat pulmonary arterial hypertension (PAH) [3]. PAH is a serious condition characterized by high blood pressure in the arteries of the lungs [3].
Who Makes Uptravi?
Uptravi is manufactured by Actelion Pharmaceuticals [3].
How Does Uptravi Work?
Uptravi works by activating prostacyclin receptors in the blood vessels of the lungs. This action helps to relax and widen these vessels, reducing the pressure and improving blood flow [3].
What are the Risks or Side Effects of Uptravi?
Common side effects associated with Uptravi include headache, diarrhea, nausea, vomiting, jaw pain, muscle pain, and pain in extremity [3]. Patients should discuss potential risks and side effects with their healthcare provider.
What Other Treatments Exist for Pulmonary Arterial Hypertension?
Other treatment options for PAH include prostacyclin pathway agonists, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors [4]. The choice of treatment depends on the individual patient's condition and medical history.
---
Sources:
[1] DrugPatentWatch.com
[2] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generics-and-biosimilars-overview
[3] https://www.uptravi.com/
[4] https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20351177